<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">In this paper, we present several documents or informational materials related to the regulatory environment around the development and management of medical products concerning the COVID-19 pandemic. Some of these documents refer to actions, initiatives, or exceptional approaches where health or regulatory authorities have either: (1) advanced existing initiatives aimed at agile and responsive regulatory systems and processes; or (2) introduced new and innovative ways to expedite and improve such processes. For the purpose of this review, we refer to 
 <italic>regulatory agility</italic> as the willingness of authorities to take quick action within the accepted regulatory framework to ensure that the regulatory ecosystem swiftly responds to the challenges imposed by the pandemic for the ultimate benefit of patients and society as a whole.
</p>
